#1 Clinical Trials Search in Europe

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

3 1 1

What is this study about?

This clinical trial is focused on studying Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness and degeneration. The study is testing a treatment called eteplirsen, which is administered as a solution for infusion. Eteplirsen is designed to help certain patients with DMD who have specific genetic mutations that can be treated by skipping exon 51, a part of the gene involved in the disease.

The purpose of the study is to evaluate the safety and effectiveness of different doses of eteplirsen. The study begins with an open-label phase, where all participants receive increasing doses of eteplirsen to assess how well they tolerate the treatment. Following this, there is a double-blind phase, where participants are randomly assigned to receive either a high dose or a lower dose of eteplirsen, or a placebo, without knowing which one they are receiving. This phase aims to compare the effects of the different doses on the motor function of patients who can walk and have the specific genetic mutations suitable for exon 51 skipping.

Throughout the study, participants will receive weekly intravenous infusions of eteplirsen. The study will monitor various health indicators, including motor function tests and safety assessments, over a period of time to determine the impact of the treatment. The study is expected to continue until 2026, providing valuable information on the potential benefits and risks of eteplirsen for treating Duchenne Muscular Dystrophy.

1 joining the study

Upon joining the study, participation begins with an open-label dose escalation phase. This phase involves receiving weekly intravenous doses of eteplirsen at 100 mg/kg and 200 mg/kg. The purpose is to evaluate safety and tolerability.

2 dose escalation phase

During this phase, the focus is on monitoring for any adverse events, changes in vital signs, and results from physical examinations. Regular assessments include laboratory tests, electrocardiograms (ECGs), and echocardiograms (ECHO).

3 double-blind dose finding and comparison

Following the open-label phase, the study transitions to a double-blind dose finding and comparison phase. Participants receive weekly intravenous doses of eteplirsen at either 30 mg/kg, 100 mg/kg, or 200 mg/kg. The aim is to compare the effects of different doses on motor function.

4 motor function assessment

Motor function is assessed through various tests, including the North Star Ambulatory Assessment (NSAA), time to rise from the floor, 10-meter walk/run time, 6-minute walk test, and a timed 4-step stair ascend test.

5 monitoring and safety assessments

Throughout the study, continuous monitoring for adverse events, special interest events, and serious adverse events is conducted. Safety laboratory assessments, ECGs, and ECHO are performed regularly to ensure participant safety.

6 study duration

The study is expected to continue until October 31, 2026. Participants will be involved in regular assessments and monitoring throughout this period.

Who Can Join the Study?

  • Must be a male with a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) and have a specific type of genetic change called an “out-of-frame deletion mutation” that can be treated with exon 51 skipping.
  • Must be between 4 and 13 years old.
  • Must be able to walk and perform a specific test called TTRISE in 10 seconds or less during the screening visit.
  • Must be able to walk without using any assistive devices like crutches or a wheelchair.
  • Must have healthy right and left biceps muscles or another upper arm muscle that can be used for a muscle biopsy, which is a small sample of muscle tissue taken for testing.
  • Must have been taking a stable dose of oral corticosteroids, which are a type of medication, for at least 12 weeks before starting the study, and the dose should stay the same during the study.
  • If 7 years or older, must have stable lung function, meaning the lungs are working well enough, and not need help with breathing at night. If between 4 to 6 years old, must not need a ventilator or other breathing support at the time of screening.
  • If sexually active, must agree to use a male condom during sexual activity for the entire study and for 90 days after the last dose. The partner must also use a medically approved form of birth control.
  • Must have a parent or legal guardian who can understand and follow all the study requirements.
  • Must be willing to give informed assent, which means agreeing to participate, and have a parent or legal guardian willing to give informed consent for participation in the study.

Who Cannot Join the Study?

  • Patients who are not male cannot participate in the study.
  • Patients who do not have Duchenne Muscular Dystrophy cannot participate in the study.
  • Patients who are not within the specified age range cannot participate in the study.
  • Patients who do not have a confirmed genetic deletion that can be treated with Exon 51 skipping cannot participate in the study. Exon 51 skipping is a specific genetic treatment approach for certain types of Duchenne Muscular Dystrophy.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hospital Universitario Y Politecnico La Fe Valencia Spain

Other Sites

Site Name City Country Status
Hospital Sant Joan De Deu Barcelona Esplugues De Llobregat Spain
Helse Stavanger HF Stavanger Norway
Centrul National Clinic De Recuperare Neuropsihomotorie Copii Dr. Nicolae Robanescu Bucharest Romania
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Fakultni Nemocnice Brno Brno Czechia
Semmelweis University Budapest Hungary
Stichting Radboud University Medical Center Nijmegen The Netherlands
IRCCS Ospedale Policlinico San Martino Genoa Italy
University Medical Center Ljubljana Ljubljana Slovenia
Rigshospitalet Copenhagen Denmark
Association Institut De Myologie Paris France
Iymy Gfmig Filothei Greece
Fgeqvlqo nwkvtwvsy Mefrf a Havvzec Prague Czechia
Udydwraicttsff Czdgpce Kkhbnsbit Gdansk Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Czechia Czechia
Not recruiting
31.05.2022
Denmark Denmark
Not recruiting
31.05.2022
France France
Not recruiting
31.05.2022
Germany Germany
Not recruiting
31.05.2022
Greece Greece
Not recruiting
31.05.2022
Hungary Hungary
Not recruiting
31.05.2022
Italy Italy
Not recruiting
31.05.2022
Norway Norway
Not recruiting
31.05.2022
Poland Poland
Not recruiting
31.05.2022
Romania Romania
Not recruiting
31.05.2022
Slovenia Slovenia
Not recruiting
31.05.2022
Spain Spain
Not recruiting
31.05.2022
The Netherlands The Netherlands
Not recruiting
31.05.2022

Trial locations

Investigated drugs:

Eteplirsen is a medication being studied for its potential to help patients with Duchenne Muscular Dystrophy (DMD). This condition is a genetic disorder characterized by progressive muscle degeneration and weakness. Eteplirsen is designed to target specific genetic mutations that are amenable to exon 51 skipping, which may help improve muscle function. The trial involves administering eteplirsen through weekly intravenous (IV) doses to evaluate its safety, tolerability, and effectiveness in improving motor function in patients with DMD.

Investigated diseases:

Duchenne Muscular Dystrophy – Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive muscle weakness and degeneration. It primarily affects boys and is caused by mutations in the dystrophin gene, which is crucial for maintaining muscle cell structure. Symptoms usually begin in early childhood, with affected individuals experiencing difficulty in walking, running, and jumping. As the disease progresses, muscle weakness spreads to the arms, neck, and other areas, leading to loss of mobility. Over time, individuals may also experience complications in the heart and respiratory muscles. The progression of muscle weakness varies, but it generally leads to significant physical disability.

Trial ID:
2024-511492-15-00
Protocol code:
4658-402
NCT ID:
NCT03992430
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of SAT-3247 Compared to Placebo for Patients with Duchenne Muscular Dystrophy Who Can Walk

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland Spain

  • Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy The Netherlands Spain